{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:16:10Z","timestamp":1771935370049,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"DOI":"10.7759\/cureus.104172","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:16:59Z","timestamp":1771931819000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinico-Microbiological Profile of Carbapenem-Resistant Acinetobacter baumannii Isolates From Intensive Care Unit Patients and In Vitro Activity of Sulbactam-Durlobactam: A Cross-Sectional Study From Eastern India"],"prefix":"10.7759","author":[{"given":"A.","family":"Susanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nipa","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ipsa","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujit","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhra Snigdha","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipti","family":"Pattnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pragyan Parimita","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","unstructured":"Global burden of bacterial antimicrobial resistance in 2019. a systematic analysis. Lancet. 2022, 399:629-55. 10.1016\/S0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"ref2","unstructured":"World Health Organization. Antimicrobial resistance. (2023). Accessed. January 19, 2026: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12091920","article-title":"An overview of the recent advances in antimicrobial resistance","volume":"12","author":"Oliveira M","year":"2024","unstructured":"Oliveira M, Antunes W, Mota S, Madureira-Carvalho \u00c1, Dinis-Oliveira RJ, Dias da Silva D. An overview of the recent advances in antimicrobial resistance. Microorganisms. 2024, 12:1920. 10.3390\/microorganisms12091920","journal-title":"Microorganisms"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012270","article-title":"How can we escape the ESKAPEs: antimicrobial resistance mechanisms and what lies ahead?","volume":"20","author":"Kelly JB","year":"2024","unstructured":"Kelly JB, Nolan AC, Zeden MS. How can we escape the ESKAPEs: antimicrobial resistance mechanisms and what lies ahead?. PLoS Pathog. 2024, 20:e1012270. 10.1371\/journal.ppat.1012270","journal-title":"PLoS Pathog"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2024.106674","article-title":"An insight into MDR Acinetobacter baumannii infection and its pathogenesis: potential therapeutic targets and challenges","volume":"192","author":"Singh S","year":"2024","unstructured":"Singh S, Singh S, Trivedi M, Dwivedi M. An insight into MDR Acinetobacter baumannii infection and its pathogenesis: potential therapeutic targets and challenges. Microb Pathog. 2024, 192:106674. 10.1016\/j.micpath.2024.106674","journal-title":"Microb Pathog"},{"key":"ref6","unstructured":"Centers for Disease Control and Prevention. Carbapenem-resistant Acinetobacter baumannii (CRAB). an urgent public health threat in United States healthcare facilities. (2021). Accessed: January 19, 2026: https:\/\/arpsp.cdc.gov\/story\/cra-urgent-public-health-threat."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111367","article-title":"Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens","volume":"27","author":"Thacharodi A","year":"2024","unstructured":"Thacharodi A, Vithlani A, Hassan S, Alqahtani A, Pugazhendhi A. Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens. iScience. 2024, 27:111367. 10.1016\/j.isci.2024.111367","journal-title":"iScience"},{"key":"ref8","unstructured":"Indian Council of Medical Research. Annual report. Antimicrobial Resistance Research and Surveillance Network (AMRSN), 8th edition. (2024). Accessed: January 19, 2026: https:\/\/www.icmr.gov.in\/icmrobject\/uploads\/Report\/1763981012_icmramrsnannualreport2024.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10749-1","article-title":"Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022","volume":"25","author":"Lodise TP","year":"2025","unstructured":"Lodise TP, Nguyen ST, Margiotta C, Cai B. Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022. BMC Infect Dis. 2025, 25:549. 10.1186\/s12879-025-10749-1","journal-title":"BMC Infect Dis"},{"key":"ref10","unstructured":"World Health Organization. WHO updates list of drug-resistant bacteria most threatening to human health. (2024). Accessed. January 19, 2026: https:\/\/www.who.int\/news\/item\/17-05-2024-who-updates-list-of-drug-resistant-bacteria-most-threatening-to-human-health."},{"key":"ref11","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. (2019). Accessed. January 19, 2026: https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/2019-ar-threats-report-508.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10030373","article-title":"Acinetobacter baumannii antibiotic resistance mechanisms","volume":"10","author":"Kyriakidis I","year":"2021","unstructured":"Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens. 2021, 10:373. 10.3390\/pathogens10030373","journal-title":"Pathogens"},{"key":"ref13","unstructured":"World Health Organization. Antimicrobial resistance. accelerating national and global responses. (2024). Accessed: January 19, 2026: https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA77\/A77_5-en.pdf."},{"key":"ref14","unstructured":"World Health Organization. One Health. (2023). Accessed. January 19, 2026: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/one-health."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01086-24","article-title":"New perspectives on antimicrobial agents: sulbactam-durlobactam","volume":"69","author":"Pogue JM","year":"2025","unstructured":"Pogue JM, Harrington J, Wangchinda W, Kaye KS. New perspectives on antimicrobial agents: sulbactam-durlobactam. Antimicrob Agents Chemother. 2025, 69:e0108624. 10.1128\/aac.01086-24","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye KS","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG, et al.. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023, 23:1072-84. 10.1016\/S1473-3099(23)00184-6","journal-title":"Lancet Infect Dis"},{"key":"ref17","article-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute","year":"2024","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute, Wayne, PA; 2024."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1045206","article-title":"Carbapenem-resistant Acinetobacter baumannii: a challenge in the intensive care unit","volume":"13","author":"Jiang Y","year":"2022","unstructured":"Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem-resistant Acinetobacter baumannii: a challenge in the intensive care unit. Front Microbiol. 2022, 13:1045206. 10.3389\/fmicb.2022.1045206","journal-title":"Front Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-025-01580-7","article-title":"Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens","volume":"15","author":"Chen CL","year":"2025","unstructured":"Chen CL, Yang KY, Peng CK, et al.. Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens. Ann Intensive Care. 2025, 15:162. 10.1186\/s13613-025-01580-7","journal-title":"Ann Intensive Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_2085_17","article-title":"Molecular characterization & epidemiology of carbapenem-resistant Acinetobacter baumannii collected across India","volume":"149","author":"Vijayakumar S","year":"2019","unstructured":"Vijayakumar S, Mathur P, Kapil A, et al.. Molecular characterization & epidemiology of carbapenem-resistant Acinetobacter baumannii collected across India. Indian J Med Res. 2019, 149:240-6. 10.4103\/ijmr.IJMR_2085_17","journal-title":"Indian J Med Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0317798","article-title":"Predominance of extensively-drug resistant Acinetobacter baumannii carrying bla OXA-23 in Jordanian patients admitted to the intensive care units","volume":"20","author":"Ababneh Q","year":"2025","unstructured":"Ababneh Q, Aldaken N, Jaradat Z, et al.. Predominance of extensively-drug resistant Acinetobacter baumannii carrying bla OXA-23 in Jordanian patients admitted to the intensive care units. PLoS One. 2025, 20:e0317798. 10.1371\/journal.pone.0317798","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf134","article-title":"The global epidemiology of carbapenem-resistant Acinetobacter baumannii","volume":"7","author":"Boutzoukas A","year":"2025","unstructured":"Boutzoukas A, Doi Y. The global epidemiology of carbapenem-resistant Acinetobacter baumannii. JAC Antimicrob Resist. 2025, 7:dlaf134. 10.1093\/jacamr\/dlaf134","journal-title":"JAC Antimicrob Resist"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9129083","article-title":"High prevalence and endemicity of multidrug resistant Acinetobacter spp. in intensive care unit of a tertiary care hospital, Varanasi, India","volume":"2018","author":"Banerjee T","year":"2018","unstructured":"Banerjee T, Mishra A, Das A, Sharma S, Barman H, Yadav G. High prevalence and endemicity of multidrug resistant Acinetobacter spp. in intensive care unit of a tertiary care hospital, Varanasi, India. J Pathog. 2018, 2018:9129083. 10.1155\/2018\/9129083","journal-title":"J Pathog"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00781-22","article-title":"In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021","volume":"66","author":"Karlowsky JA","year":"2022","unstructured":"Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021. Antimicrob Agents Chemother. 2022, 66:e0078122. 10.1128\/aac.00781-22","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/0972-5229.117036","article-title":"Carbapenem-resistant Acinetobacter ventilator-associated pneumonia: clinical characteristics and outcome","volume":"17","author":"Gurjar M","year":"2013","unstructured":"Gurjar M, Saigal S, Baronia AK, Rao BP, Azim A, Poddar B, Singh RK. Carbapenem-resistant Acinetobacter ventilator-associated pneumonia: clinical characteristics and outcome. Indian J Crit Care Med. 2013, 17:129-34. 10.4103\/0972-5229.117036","journal-title":"Indian J Crit Care Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad096","article-title":"Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization","volume":"5","author":"Cogliati Dezza F","year":"2023","unstructured":"Cogliati Dezza F, Covino S, Petrucci F, et al.. Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization. JAC Antimicrob Resist. 2023, 5:dlad096. 10.1093\/jacamr\/dlad096","journal-title":"JAC Antimicrob Resist"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14050490","article-title":"Prevalence of Acinetobacter baumannii multidrug resistance in university hospital environment","volume":"14","author":"Foglia F","year":"2025","unstructured":"Foglia F, Ambrosino A, Bashir S, et al.. Prevalence of Acinetobacter baumannii multidrug resistance in university hospital environment. Antibiotics (Basel). 2025, 14:490. 10.3390\/antibiotics14050490","journal-title":"Antibiotics (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/464137-clinico-microbiological-profile-of-carbapenem-resistant-acinetobacter-baumannii-isolates-from-intensive-care-unit-patients-and-in-vitro-activity-of-sulbactam-durlobactam-a-cross-sectional-study-from-eastern-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:17:04Z","timestamp":1771931824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/464137-clinico-microbiological-profile-of-carbapenem-resistant-acinetobacter-baumannii-isolates-from-intensive-care-unit-patients-and-in-vitro-activity-of-sulbactam-durlobactam-a-cross-sectional-study-from-eastern-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.104172","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}